Amlexanox, an IKBKE/TBK1 inhibitor developed to treat ulcers, allergic rhinitis and asthma, results in a G0/G1 arrest in glioblastoma cells and induction of apoptosis (13). Here, IKBKE is linked to ulcer disease.